Anti-thymocyte globulin (rabbit) is under clinical development by Neovii Pharmaceuticals and currently in Phase III for Myelodysplastic Syndrome.

The polyclonal antibodies currently available are all antithymocyte globulins (ATGs) obtained by immunization of rabbits (rATG) or horses (equine ATG). These species are used because they produce ...